About the Company
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
26
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ELOX News
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome ...
Why Eloxx Pharmaceuticals (ELOX) Stock Is Soaring Tuesday
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) shares are rocketing higher on Tuesday after Oppenheimer raised its price target from $50 to $55. The Details: Oppenheimer analyst Hartaj Singh ...
Eloxx Pharmaceuticals Inc ELOX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents ...
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) (“Eloxx” or the “Company”), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the U.S. Food and Drug ...
BSPM Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People’s Republic of ...
Eloxx Pharmaceuticals Inc ELOX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
As part of this agreement, Eloxx will receive an upfront of $3 ... Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists ...
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
April 16, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today provided program updates for ELX-02 and ...
Eloxx Pharmaceuticals Inc (ELOX)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Eloxx Pharmaceuticals, Inc. (ELOX)
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready ...
Eloxx Pharmaceuticals, Inc. (ELOX)
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready ...
Loading the latest forecasts...